Libor Havel
- Oncology top 2%
- Lung Cancer Research Studies 27
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 7
- Pancreatic and Hepatic Oncology Research 5
-
- Lung Cancer Treatments and Mutations 31
- Lung Cancer Diagnosis and Treatment 13
- Otorhinolaryngology top 10%
- Epidemiology top 10%
- Neuroendocrine Tumor Research Advances 6
- Radiation top 10%
-
- Cancer therapeutics and mechanisms 8
- Co-authors
- Luboš PetruželkaPetr ZatloukalMilada ZemanováA KubíkE Kr̆epelaLibor JudasLadislav PecenFilip Jankú
- Journals
- Annals of Oncology (13 papers)Journal of Clinical Oncology (12 papers)Lung Cancer (8 papers)
- Partner nations
- CzechiaUnited StatesGermany
In The Last Decade
Libor Havel
48 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 69
- Oncology 1.2k
- Pulmonary and Respiratory Medicine 980
- Otorhinolaryngology 50
- Epidemiology 392
- Radiation 83
Countries citing papers authored by Libor Havel
This map shows the geographic impact of Libor Havel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libor Havel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libor Havel more than expected).
Fields of papers citing papers by Libor Havel
This network shows the impact of papers produced by Libor Havel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libor Havel. The network helps show where Libor Havel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Libor Havel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 23 | |
| 2 | LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLCbreakdown → | 2023 | 67 |
| 3 | 2023 | 0 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 23 | |
| 6 | 2023 | 7 | |
| 7 | 2022 | 49 | |
| 8 | 2022 | 7 | |
| 9 | 2022 | 0 | |
| 10 | 2022 | 27 | |
| 11 | 2020 | 7 | |
| 12 | 2019 | 8 | |
| 13 | 2018 | 5 | |
| 14 | 2017 | 1 | |
| 15 | Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancerbreakdown → | 2016 | 397 |
| 16 | 2014 | 14 | |
| 17 | 2013 | 30 | |
| 18 | 2004 | 329 | |
| 19 | Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial | 2003 | 41 |
| 20 | 2003 | 139 |
About Libor Havel
Libor Havel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Applied Microbiology and Biotechnology, Genetics and Biotechnology, having authored 54 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (27 papers), Lung Cancer Diagnosis and Treatment (13 papers), Cancer Immunotherapy and Biomarkers (10 papers), Cancer therapeutics and mechanisms (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Neuroendocrine Tumor Research Advances (6 papers) and Pancreatic and Hepatic Oncology Research (5 papers). The work is most often cited by research in Oncology (1.2k citations), Pulmonary and Respiratory Medicine (980 citations), Otorhinolaryngology (50 citations), Epidemiology (392 citations) and Radiation (83 citations). Libor Havel has collaborated with scholars based in Czechia, United States and Germany. Frequent co-authors include Luboš Petruželka, Petr Zatloukal, Milada Zemanová, A Kubík, E Kr̆epela, Libor Judas, Ladislav Pecen, Filip Jankú, Pavel Fiala and Yi‐Long Wu. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Lung Cancer, Journal of Thoracic Oncology and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.